Aptima HPV Assay versus Hybrid Capture^® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial

详细信息    查看全文

• 作者：Darrel A. Cook^a ; ^b ; Laurie W. Smith^a ; Jennifer Law^c ; Wendy Mei^c ; Dirk J. van Niekerk^a ; ^c ; ^d ; Kathy Ceballos^a ; ^c ; ^d ; Lovedeep Gondara^a ; Eduardo L. Franco^e ; Andrew J. Coldman^a ; ^d ; Gina S. Ogilvie^b ; ^d ; Dan Jang^f ; Max Chernesky^f ; Mel Krajden^b ; ^c ; ^d ; ^{mel.krajden@bccdc.ca} ; ^{mel.krajden@gmail.com}
• 关键词：hr ; high-risk ; HPV ; human papillomavirus ; CIN ; cervical intraepithelial neoplasia ; AHPV ; Aptima HPV Assay ; HC2 ; Hybrid Capture® ; 2 HPV Test ; LBC ; liquid-based cytology ; HC2+ ; HC2 positive ; ASCUS ; atypical squamous cells ; undetermined significance ; NILM ; negative for intraepithelial lesions or malignancy ; HC2&minus ; HC2 negative ; AHPV-G ; Aptima HPV 16 18/45 Genotype Assay ; RLU/CO ; relative light units/cutoff ; CI ; confidence interval ; UNSAT ; smear unsatisfactory ; AGC ; atypical glandular cells
• 刊名：Journal of Clinical Virology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：87
• 期：Complete
• 页码：23-29
• 全文大小：690 K
• 卷排序：87

文摘

Aptima HPV had a lower positivity rate and higher specificity vs. hybrid capture 2. Aptima HPV and hybrid capture 2 had equivalent CIN2+ detection. CIN2+ detection increased by including HPV 16/18/45 genotyping with cytology triage. Colposcopy referral rate was significantly lower for Aptima vs. hybrid capture 2.